Zobrazeno 1 - 10
of 1 501
pro vyhledávání: ''
Autor:
Laura E. Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Dominik P. Modest, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Clemens Giessen-Jung, Jens Uhlig, Bettina Peuser, Claudio Denzlinger, Arndt Stahler, Lena Weiss, Kathrin Heinrich, Swantje Held, Andreas Jung, Thomas Kirchner, Volker Heinemann
Publikováno v:
British Journal of Cancer. 127:836-843
Summary Background The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab
Autor:
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, Hee Kyung Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was condu
Autor:
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Yoshinori Okubo, Jun Nakamura, Mika Takasumi, Minami Hashimoto, Tsunetaka Kato, Ryoichiro Kobashi, Takuto Hikichi, Hiromasa Ohira
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemother
Autor:
In Gyu Hwang, Sang-Cheol Lee, Yaewon Yang, Sung Yong Oh, Sang-Gon Park, So Yeon Jeon, Dae Young Zang, Jung Hun Kang, Jun Ho Ji, Hyun Woo Lee, Woo Kyun Bae, Sun Jin Sym, Se-Il Go, Joung Soon Jang, Jung Hoon Kim
Publikováno v:
European Journal of Cancer. 157:21-30
Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFO
Autor:
Clemens Gießen-Jung, Thomas Decker, Andreas Jung, Ullrich Graeven, Jens Neumann, Ingo Schwaner, A. Stahler, Annika Kurreck, Thomas Kirchner, Dominik Paul Modest, Michael Schenk, Veronika Schuster, C. Denzlinger, Kathrin Heinrich, Volker Heinemann, Swantje Held, Florian Kaiser, Ludwig Fischer von Weikersthal, Jörg Kumbrink, Sebastian Stintzing
Publikováno v:
European Journal of Cancer. 157:71-80
Background The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naive metastatic colorectal cancer (mCRC). In t
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Minghua Ge, Yan-Yan Liu, Zhengdong Li, Liangfang Shen, Qingyuan Zhang, Yi Luo, Jifeng Feng, Ye Guo, W. Chen, Kun-Yu Yang, Xiaohui He, Kai Xue, Yan Sun, T. Lin, Xiao-Dong Zhu, Xiao Ming Huang, XinYing Chang, Chunmei Bai, Yan Zeng, Lin Wang
Publikováno v:
European Journal of Cancer. 156:35-45
Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/
Autor:
Chia Jui Yen, James J. Harding, Stacey A. Cohen, Mehmet Akce, Yin Hsun Feng, Shukui Qin, Wen Tsung Huang, Imane El Dika, Ghassan K. Abou-Alfa, Tim Meyer, Dae Won Lee, Amanda Johnston, John S. Bomalaski, Debashis Sarker, Benjamin R. Tan, Baek Yeol Ryoo, Eileen M. O'Reilly, Yen Yang Chen, Ho Yeong Lim, Ching Liang Ho, Tsai Sheng Yang
Publikováno v:
Cancer. 127:4585-4593
Background Arginine starvation depletes the micronutrients required for DNA synthesis and interferes with both thymidylate synthetase activity and DNA repair pathways in preclinical models of hepatocellular carcinoma (HCC). Pegylated arginine deimina
Autor:
Veronica Conca, Matteo Clavarezza, Chiara Cremolini, Alessandra Boccaccino, Filippo Pietrantonio, Roberto Moretto, Cristina Granetto, Gianluca Tomasello, Alessandro Bertolini, Antonio Frassoldati, Alfredo Falcone, Mirella Giordano, Alessandro Passardi, Sara Lonardi, Anello Marcello Poma, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Giuseppe Aprile, Marco Maria Germani
Publikováno v:
European Journal of Cancer. 153:16-26
Background Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. Patients